Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors
Cell Chemical Biology · 2025
DOI: 10.1016/j.chembiol.2025.09.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Chemical Biology, 2025. Verfasst von Raquel Pequerul und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Faculty of Biosciences, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193 Barcelona, …. Hauptthemen laut MEDLINE: Breast Neoplasms, Aldehyde Dehydrogenase 1 Family, Antineoplastic Agents, Enzyme Inhibitors. Die Arbeit nennt 87 Literaturangaben. Gefördert von: Agencia Estatal de Investigación, Spain Ministry of Science and Innovation, French National Research Agency.
Abstract (Originalsprache)
Basal-like breast cancer is an aggressive subtype with limited therapeutic options. Here, transcriptomic analysis of public datasets suggested distinct subtype- and cell-specific expression patterns of ALDH1A isoforms in breast tumors, with ALDH1A3 predominantly expressed in the epithelial cells of basal-like tumors, whereas ALDH1A2 and ALDH1A1 were enriched in stromal and immune-associated subpopulations. High expression of ALDH1A3 and ALDH1A2, but not ALDH1A1, is associated with poor prognosis in high-grade, lymph-node-positive tumors. To evaluate therapeutic targeting, we developed ABD0171, an irreversible, selective ALDH1A3 inhibitor with additional ALDH1A1 activity. ABD0171 disrupted key oncogenic pathways, including IL6/JAK/STAT3, tPA, and Src/FAK, resulting in robust antitumor and antimetastatic effects in vitro and in vivo, with a favorable safety profile. These findings establish ALDH1A3 as a therapeutic target in breast cancers with epithelial-basal traits and validate ABD0171 as a promising clinical candidate to address current treatment challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Faculty of Biosciences, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193 Barcelona, Spain; Advanced BioDesign, 69800 Saint Priest, France.
- Advanced BioDesign, 69800 Saint Priest, France.
- Department of Cancer Research, Tumor Immunotherapy and Microenvironment (TIME) Group, Luxembourg Institute of Health (LIH), 1210 Luxembourg City, Luxembourg.
- Aix-Marseille University, INSERM, TAGC, UMR1090, 13266 Marseille, France.
- Department of Biochemistry and Molecular Biology, Faculty of Biosciences, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193 Barcelona, Spain.
- Department of Chemistry, Faculty of Sciences, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, 08193 Barcelona, Spain.
Förderung
- Agencia Estatal de Investigación
- Spain Ministry of Science and Innovation
- French National Research Agency
Zitieren
APA
Pequerul, R., Constantinescu, A., Janji, B., Kumar, A., Baier, C., Manosalva, I., Parés, X., Palacios, O., Spicuglia, S., Colignon, D., Berrou, A., Fournet, G., Berchard, P., Martin, G., Ceylan, I., Rebollido-Rios, R., Farrés, J., & Perez-Alea, M. (2025). Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. Cell Chemical Biology. https://doi.org/10.1016/j.chembiol.2025.09.003
Vancouver
Pequerul R, Constantinescu A, Janji B, Kumar A, Baier C, Manosalva I, et al. Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. Cell Chemical Biology. 2025. doi:10.1016/j.chembiol.2025.09.003
BibTeX
@article{Pequerul2025,
author = {Pequerul, Raquel and Constantinescu, Andrada and Janji, Bassam and Kumar, Akinchan and Baier, Céline and Manosalva, Iris and Parés, Xavier and Palacios, Oscar and Spicuglia, Salvatore and Colignon, Delphine and Berrou, Axelle and Fournet, Guy and Berchard, Paul and Martin, Guillaume and Ceylan, Ismail and Rebollido-Rios, Rocio and Farrés, Jaume and Perez-Alea, Mileidys},
title = {Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors},
journal = {Cell Chemical Biology},
year = {2025},
doi = {10.1016/j.chembiol.2025.09.003}
}
EUVIMED